Generation of HER-2/neu-Specific Cytotoxic Neutrophils in Vivo: Efficient Arming of Neutrophils by Combined Administration of Granulocyte Colony-Stimulating Factor and Fcγ Receptor I Bispecific Antibodies

Journal of Immunology

Volumn 159, Issue 11, 1997, Pages 5629-5639

  Heijnen, Ingmar A F M ^a   Rijks, Leonie J M ^b   Schiel, Anja ^c   Stockmeyer, Bernhard ^c   Van Ojik, Heidi H ^a   Dechant, Michael ^c   Valerius, Thomas ^c   Keler, Tibor ^d   Tutt, Alison L ^e   Glennie, Martin J ^e   Van Royen, Eric A ^b   Capel, Peter J A ^a   Van De Winkel, Jan G J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d MEDAREX INC   (United States)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL CULTURE; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NEUTROPHIL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MICE; MICE, TRANSGENIC; NEUTROPHILS; RECEPTOR, ERBB-2; RECEPTORS, IGG; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0031297669     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Dillman, R. O. 1994. Antibodies as cytotoxic therapy. J. Clin. Oncol. 12:1497.
2. Iliopoulos, D., C. Ernst, Z. Steplewski, J. A. Jambrosic, U. Rodeck, M. Herlyn, W. H. Clark, Jr., H. Koprowski, and D. Herlyn. 1989. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J. Natl. Cancer Inst.. 81:440
3. Schreiber, G. J., K. E. Hellström, and I. Hellström. 1992. An unmodified anti-carcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res. 52:3262.
4. Kasprzyk, P. G., S. U. Song, P. P. Di Fiore, and C. R. King. 1992. Therapy of an animal model of human gastric cancer using a combination of anti-erbB2 monoclonal antibodies. Cancer Res. 52:2771.
5. Riethmüller, G., E. Schneider-Gädicke, G. Schlimok, W. Schmiegel, R. Raab, K. Höffken, R. Gruber, H. Pichlmaier, H. Hirche, R. Pichlmayr, P. Buggisch, J. Witte, and the German Cancer Aid 17-1A Study Group. 1994. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177.
6. 2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res. 49:3095.
7. Neal, C. E., M. R. Baker, R. D. Hilgers, J. Fanning, R. C. Burke, J. Snodgrass, and R. D. Cull. 1993. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma. Clin. Nucl. Med. 18:472.
8. Perez-Solar, R., N. J. Donato, D. M. Shin, M. G. Rosenblum, H.-Z. Zhang, C. Tornos, H. Brewer, J. C. Chan, J. S. Lee, W. K. Hong, and J. L. Murray. 1994. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J. Clin. Oncol. 12:730.
9. Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. Nature 332:323.
10. Hakimi, J., R. Chizzonite, D. R. Luke, P. C. Familletti, P. Bailon, J. A. Kondas, R. S. Pilson, P. Lin, D. V. Weber, C. Spence, L. J. Mondini, W. Tsien, J. L. Levin, V. H. Gallati, L. Korn, T. A. Waldmann, C. Queen, and W. R. Benjamin. 1991. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol. 147:1352.
11. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737.
12. Mueller, B. M., C. A. Romerdahl, S. D. Gillies, and R. A. Reisfeld. 1990. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J. Immunol. 144:1382.
13. Tokuda, Y., Y. Ohnishi, K. Shimamura, M. Iwasawa, M. Yoshimura, Y. Ueyama, N. Tamaoki, T. Tajima, and T. Mitomi. 1996. In vitro and in vivo anti-tumor etfects of a humanised monoclonal antibody against c-erbB-2 product. Br. J. Cancer 73:1362.
14. Wallace, P. K., A. L. Howell, and M. W. Fanger. 1994. Role of Fc receptors in cancer and infectious disease. J. Leukocyte Biol. 55:816.
15. Van de Winkel, J. G. J., and P. J. A. Capel. 1993. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 14: 215.
16. Lieschke, G. J., and A. W. Burgess. 1992. Drug therapy: granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor (I + II). N. Engl. J. Med. 327:28.
17. Valerius, T., R. Repp, T. P. M. de Wit, S. Berthold, E. Platzer, J. R. Kalden, M. Gramatzki, and J. G. J. van de Winkel. 1993. Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82:931.
18. Lichtenstein, A. 1990. Granulocytes as possible effectors of tumor immunity. In Human Cancer Immunology, Vol. 1. H. F. Oettgen, ed. W. B. Saunders, Philadelphia, p. 731.
19. Midorikawa, Y., T. Yamashita, and F. Sendo. 1990. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res. 50:6243.
20. Seino, K.-I., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165.
21. Stockmeyer, B., T. Valerius, R. Repp, I. A. F. M. Heijnen, H.-J. Bühring, Y. M. Deo, J. R. Kalden, M. Gramatzki, and J. G. J. van de Winkel. 1997. Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res. 57:696.
22. Deo, Y. M., R. F. Graziano, R. Repp, and J. G. J. Van de Winkel. 1997. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol. Today 18:127.
23. Coussens, L., T. L. Yang-Feng, Y. L. E. Chen, A. Gray, J. McGrath, P. H. Seeburg, T. A. Liberman, J. Schlessinger, U. Francke, A. Levinson, and A. Ullrich. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132.
24. Slamon, D., G. Clark, S. Wong, W. Levin, A. Ullrich, and W. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177.
25. Valone, F. H., P. A. Kaufman, P. M. Guyre, L. D. Lewis, V. Memoli, Y. Deo, R. Graziano, J. L. Fisher, L. Meyer, M. Mrozek-Orlowski, K. Wardwell, V. Guyre, T. L. Morley, C. Arvizu, and M. W. Fanger. 1995. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13:2281.
26. r 200,000 glycoprotein selectively associated with human breast cancer. Cancer Res. 49:3070.
27. Elsässer, D., T. Valerius, R. Repp, G. J. Weiner, Y. Deo, J. R. Kalden, J. G. J. van de Winkel, G. T. Stevenson, M. J. Glennie, and M. Gramatzki. 1996. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 87:3803.
28. Graziano, R. F., P. R. Tempest, P. White, T. Keler, Y. Deo, H. Ghebremanam, K. Coleman, L. C. Pfefferkorn, M. W. Fanger, and P. M. Guyre. 1996. Construction and characterization of a humanized anti-γ-Ig receptor type I (FcγRI) monoclonal antibody. J. Immunol. 155:4996.
29. 3 antibody derivates. In Tumour Immunobiology, a Practical Approach. G. Gallagher, R. C. Rees, and C. W. Reynolds, eds. Oxford University Press, Oxford, U.K., p. 225.
30. Ellis, J. H., K. A. Barber, A. Tutt, C. Hale, A. P. Lewis, M. J. Glennie, G. T. Stevenson, and J. S. Crowe. 1995. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol. 155:925.
31. Heijnen, I. A. F. M., and J. G. I. van de Winkel. 1995. A human FcγRI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics. J. Hematother. 4:351.
32. Heijnen, I. A. F. M., M. J. van Vugt, N. A. Fanger, R. F. Graziano, T. P. M. de Wit, F. M. A. Hofhuis, P. M. Guyre, P. J. A. Capel, J. S. Verbeek, and J. G. J. van de Winkel. 1996. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97:331.
33. Van Strijp, J. A. G., K. P. M. van Kessel, M. E. van der Tol, and J. Verhoef. 1989. Complement-mediated phagocytosis of herpes simplex virus by human granulocytes: binding or ingestion. J. Clin. Invest. 84:107.
34. Lagasse, E., and I. L. Weissman. 1994. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J. Exp. Med. 179:1047.
35. 99mTc labeling: conjugation chemistry, immunoreactivity and kit formulation. J. Nucl. Med. 37:362.
36. Guyre, P. M., R. F. Graziano, B. A. Vance, P. M. Morganelli, and M. W. Fanger. 1989. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J. Immunol. 143:1650.
37. Van Vugt, M. J., I. A. F. M. Heijnen, P. J. A. Capel, S. Y. Park, C. Ra, T. Saito, J. S. Verbeek, and J. G. J. van de Winkel. 1996. FcR γ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo. Blood 87:3593.
38. Unkeless, J. C., E. Scigliano, and V. H. Freedman. 1988. Structure and function of human and murine receptors for IgG. Annu. Rev. Immunol. 6:251.
39. Metcalf, D., L. Robb, A. R. Dunn, S. Mifsud, and L. Di Rago. 1996. Role of granulocyte-macrophage colony-stimulating factor in the development of an acute neutrophil inflammatory response in mice. Blood 88:3755.
40. Baggiolini, M., B. Dewald, and B. Moser. 1994. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 55:97.
41. Adams, D. O., T. Hall, Z. Steplewski, and H. Koprowski. 1984. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc. Natl. Acad. Sci. USA 81:3506.
42. Hooijberg, E., J. J. Sein, P. C. M. van den Berk, A. A. M. Hart, M. A. van der Valk, W. M. Kast, C. J. M. Melief, and A. Hekman. 1995. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibody and interleukin 2. Cancer Res. 55:2627.
43. + cells in eliminating an established tumor. Eur. J. Immunol. 27:374.
44. Denkers, E. Y., C. C. Badger, J. A. Ledbetter, and I. D. Bernstein. 1985. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol. 135:2183.
45. Steplewski, Z., L. K. Sun, C. W. Shearman, J. Ghrayeb, P. Daddona, and H. Koprowski. 1988. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. USA 85:4852.
46. Ely, P., P. K. Wallace, A. L. Givan, R. F. Graziano, P. M. Guyre, and M. W. Fanger. 1996. Bispecific-armed, interferon γ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood 87:3813.
47. Daëron, M., S. Latour, O. Malbec, E. Espinosa, P. Pina, S. Pasmans, and W. H. Fridman. 1995. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3:635.
48. Schmidt, K. G., J. W. Rasmussen, I. M. Wedebye, P. B. Frederiksen, and N. T. Pedersen. 1988. Accumulation of indium-111-labeled granulocytes in malignant tumors. J. Nucl. Med. 29:479.
49. Musiani, P., A. Modesti, M. Giovarelli, F. Cavallo, M. P. Colombo, P. L. Lollini, and G. Forni. 1997. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today 18:32.
50. Weiner, L. M., J. I. Clark, M. Davey, W. S. Li, I. Garcia de Palazzo, D. B. Ring, and R. K. Alpaugh. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res. 55:4586.
51. Valerius, T, R. Repp, G. Wieland, Y. Deo, J. G. J. van de Winkel, J. R. Kalden, N. Lang, and M. Gramatzki. 1996. Bispecific antibody MDX210 (FcγRI X HER-2/neu) in combination with G-CSF: results of a phase I trial in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 15:108 (Abstr.).
52. Weber, J. S., L. Spears, Y. Deo, and J. L. Link. 1996. Phase I study of a HER-2/neu bispecific antibody with G-CSF in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 15:354 (Abstr.).